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ABSTRACT
Among all acute leukemias, acute lymphoblastic leukemia (ALL) is five times more common than acute myeloid leukemia (AML). 
Lineage switch from ALL to AML is very rare. Lineage switching is a phenomenon noted in cases of leukemias where the initially 
diagnosed cases of leukemias of a lineage (lymphoid/myeloid) present with the opposite lineage at relapse. Here, we report the case 
of a 10-year-old male child who was initially diagnosed with ALL and on relapse after 4 years, presented with AML. The blast cell 
morphology and immunophenotype were consistent with the diagnosis of typical AML.
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Acute leukemias (AL) are the most common cancer in childhood and characterized by the uncontrolled production of hematopoietic precursor cells [1]. 
Although the survival rates have increased in the last few years, 
factors such as cell lineage switching at relapses lead to poor 
prognosis [2–4]. The conversions from acute lymphoblastic 
leukemia (ALL) to acute myeloid leukemia (AML) or vice versa 
are rare and recorded as lineage switching. The exact mechanisms 
involved in these phenomena are not well defined. The prognosis 
for these patients is variable, and there is no standard treatment 
for them. In this article, we report the case of conversion of ALL 
to AML in a 10-year-old male following chemotherapy.
CASE REPORT
A 10-year-old male presented with complaints of fever for 
the last 3 months, progressive pallor since last 2 months, and 
bleeding from nose and gums since last 15 days. His appetite 
was decreased since last one month along with dizziness and 
constipation. He had received 3 units of blood, 1 week back and 
reported an episode of blood in stool, one-day before admission. 
The patient had a history of being diagnosed with ALL 4 years 
back. His bone marrow aspiration smears showed the presence 
of 95% lymphoblasts. The diagnosis of B-ALL was confirmed on 
flow cytometry with blasts showing positivity for CD34, CD45, 
CD10, CD19, CD22, CD79a. Myeloid and T-cell markers were 
negative. The patient had taken treatment for ALL for 3 years and 
remained asymptomatic for 1 year. His bone marrow examination 
was repeated post-treatment and smears showed features of 
remission with normocellular marrow and erythroid hyperplasia.
However, the patient again presented with the symptoms 
as reported earlier. Physical examination revealed pallor. No 
organomegaly was noted. Systemic examination did not reveal 
any gross abnormality and vitals were stable. Based on the past 
medical history of ALL and the presenting symptoms, a provisional 
diagnosis of “Acute leukemia with relapse” was made. 
A proper hematological examination was advised. His 
complete blood count showed a hemoglobin of 5.1gm/dl, 
total leukocyte counts (TLC) of 9000/µL and platelet count of 
20,000/µL. Peripheral smear examination showed normocytic 
normochromic red blood cells. A shift to the left was noted in 
differential leukocyte count (DLC) with the presence of 33% 
blasts. Bone marrow examination showed dilute marrow with 
scattered blasts. Flow cytometry immunophenotypic analysis was 
done. Blasts constituted 17% of total acquired events, showing 
bright positivity of CD13 and CD33 (Fig. 1A). Heterogeneous 
expression of HLA-DR and CD117 (Fig. 1B) was also noted 
along with the positivity of myeloperoxidase (Fig. 1C). Blasts 
showed negative expression of CD5, CD7, CD10, CD19, CD22, 
CD14, CD64, cCD3 (Fig. 2A-D). 
Based on flow cytometric immunophenotypic findings, a 
diagnosis of AML at relapse was made. The flow cytometric 
immunophenotypic findings of the patient at two different settings 
Figure 1A-C: Flow cytometry at relapse (AML) with blast 
cells showing positivity for CD 13, CD33, CD117, and anti-
myeloperoxidase.
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have been presented in Table 1. This type of a refractory case 
of leukemia with lineage switch required intensive combined 
chemotherapy regimen; hence, the patient was referred to a 
higher center for further management.
DISCUSSION
Acute leukemias (AL) are the most common cause of childhood 
cancer worldwide. There is uncontrolled production of 
hematopoietic precursor cells of the lymphoid or myeloid series 
within the bone marrow. It has been noted that in patients of acute 
leukemia, lineage switching occurs at relapse [1–4]. Lineage 
switching is an example of the lineage heterogeneity that exists in 
acute leukemias. A lineage switch may represent either a relapse 
of the original clone with heterogeneity at the morphological level 
or high plasticity attributes or the emergence of a new leukemic 
clone [2–6]. For example, a patient diagnosed initially with ALL 
is diagnosed with AML at relapse and vice versa.
Various mechanisms have been proposed to explain its 
etiology. Reprogramming and/or redirection of the precursor 
cell fate within bone marrow is considered one of the important 
reason behind this phenomenon [2–4]. Genetic and epigenetic 
changes in transcription factors of fully committed or developing 
cells are the basis of cellular reprogramming [3–6]. During 
dediﬀerentiation, a cellular change occurs in a diﬀerentiated state 
which in turn get back to a more primitive and less committed 
stage. Microenvironment may influence all proposed mechanisms 
by modulating the genome plasticity of the cells and change the 
leukemia outcome at relapse [5–9].
This phenomenon of lineage switch occurs when acute 
leukemias that meet the standard criteria for a lineage (lymphoid 
or myeloid) at the time of the initial diagnosis meet the criteria for 
the opposite lineage upon relapse [2–5]. In a study by Acosta et al. 
[4], eighteen cases of pediatric lineage switch have been reported. 
Conversion of ALL to AML was noted in 9 cases, AML to B-ALL 
in 5 cases and mixed phenotypic leukemia in 4 cases [4]. It has 
been noted in different studies that conversion of AML to ALL is 
rarer when compared to ALL to AML. Park et al. reported 4 cases 
of lineage switching in patients of ALL to AML [9]. A similar 
case of conversion of ALL to AML was reported by Chung et al. 
[5]. Various studies related to lineage switching in case of acute 
leukemias have been presented in Table 2.
The detailed analysis and classification of leukemia as per 
the lineage can be done by analyzing the expression of surface 
Figure 2A-D: Flow cytometric analyses of blast cells at relapse 
showed negative expression of CD5, CD7, CD10, CD19, cCD3, 
CD14& CD64.
Table 1: A table comparing the Flowcytometric immunophenotypic findings of the patient at two different admissions.
Flow cytometric  
immunophenotypic findings
Diagnosed as ALL 4 years back Diagnosed as AML  
(on relapse, 4 years post treatment)
CD34 +ve +ve
CD45 +ve +ve
CD5 -ve -ve
CD7 -ve -ve
CD10 +ve -ve
CD19 +ve -ve
CD22 +ve -ve
CD79a +ve -ve
CD13 -ve +ve
CD33 -ve +ve
CD14 -ve -ve
CD64 -ve -ve
HLA-DR +ve +ve
CD117 -ve +ve
MPO -ve +ve
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and cytoplasmic and nuclear antigens of leukemia cells. But, 
there are situations in which both lymphoid- and myeloid-
lineage markers, or T-cell and B-cell markers coexist. Some 
20–30% of patients with leukemia suﬀer relapses, during which 
it is common to find genetic alterations in the same original cell 
lineage (lymphoid or myeloid) [3–6]. In these individuals, the 
response to therapies for reinduction is usually of poorer quality 
and shorter duration. 
In ALL, the most important prognostic factor is the time to 
relapse. A higher rate of unresponsiveness to treatment along 
with lower event-free survival is noted if there is an early relapse. 
Most relapses in AML occur during treatment within the first year 
upon diagnosis [5–9]. Strikingly, neonate patients that develop 
lineage switching, present very early relapses and poor event-free 
survival, that make the prognosis for these patients poor with no 
optimal standard treatment for them [7–9].
CONCLUSION
Here, we present one case of lineage switch from ALL to AML. 
Early diagnosis is of great importance to initiate appropriate 
management without undue delay. Lineage switching has been 
reported to occur more frequently in children than adults. It is 
still not very clear that whether lineage switching is a feature 
of acute leukemia which promotes instability of hematopoietic 
lineage or it is the plasticity of AL genome following leukemic 
transformation. This phenomenon correlates with very bad 
prognosis and resistance to therapy; hence, further studies are 
appreciated to unfold the mechanisms of recurrence in cases of 
leukemias and possible implications for further management.
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Table 2: Table summarizing various studies regarding lineage switch in acute leukemia cases [1-9]
Authors Diagnosis at initial presentation Diagnosis at relapse
Acosta et al. [4], 2012 (review article) 18 cases of 
leukemia with lineage switch [1–9].
ALL-L1
AML-M5
AML-M5
B-ALL
Pro B-ALL
Pre B-ALL1
ALL
AML
Pro B-ALL L1
AML-M5
ALL-L1
B-ALL-L1
B ALL-L2
AML
ALL-L1
B ALL
T-ALL
T-ALL
AML-M5
ALL-L1
B-ALL
AML-M5
AML
AML-M4
AML-M5b
ALL-L1
AML-M0
Pro B-ALL
AML-M0
AML-M4
T-ALL
ALL
AML-M4
AML M4/M5
AML-M0
AML
Grammatico et al. [7], 2013 (1 case) Pro B-ALL AML
Wu et al. [8], 2017 (2 cases) 2 cases of ALL AML-M5 and AML-M6
Current case report B-ALL AML
